The present disclosure provides compounds of Formula (VIA), Formula (IIIA), Formula (IVA), and Formula (VA). The compounds are prodrugs of alpha-ketoglutarate, alpha-ketobutryrate, alpha-ketoisovalerate, and alpha-ketoisohexanoate, which are useful in treating or preventing age related diseases, disorders, or conditions. ##STR00001##

The present disclosure provides compounds of Formula (VIA), Formula (IIIA), Formula (IVA), and Formula (VA). The compounds are prodrugs of alpha-ketoglutarate, alpha-ketobutryrate, alpha-ketoisovalerate, and alpha-ketoisohexanoate, which are useful in treating or preventing age related diseases, disorders, or conditions. ##STR00001##

The present invention is directed to an efficient process for preparing benzoxazole derivatives comprising the step of reacting a 4-Amino-3-hydroxybenzoic acid compound of Formula III with a 3,5-Dichlorophenyl ortho ester compound of Formula I to provide the compound of Formula I

##STR00001##

wherein R.sup.1, R.sup.2a, R.sup.2b and R.sup.2c are as described herein.

Compounds and methods for purifying oligonucleotides such as RNA and DNA. A target oligonucleotide is reacted with an orthoester linker comprising an affinity tag to form an orthoester oligonucleotide-orthoester linker conjugate which is subjected to a purification technique to separate the target oligonucleotide from impurities such as truncated oligonucleotides. The orthoester linker can he then removed under mild conditions to generate the target oligonucleotide in high purity.

Compounds and methods for purifying oligonucleotides such as RNA and DNA. A target oligonucleotide is reacted with an orthoester linker comprising an affinity tag to form an orthoester oligonucleotide-orthoester linker conjugate which is subjected to a purification technique to separate the target oligonucleotide from impurities such as truncated oligonucleotides. The orthoester linker can he then removed under mild conditions to generate the target oligonucleotide in high purity.

The present disclosure relates to compounds of Formula (P) or (II′-0): (Formulae (I′), (II′-0)), and pharmaceutically acceptable salts or solvates thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds and therapeutic and diagnostic uses of the compounds and pharmaceutical compositions.

##STR00001##

The present disclosure relates to compounds of Formula (I), (II), or (II′): (I), (II), (II′), and pharmaceutically acceptable salts or solvates thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds and therapeutic and diagnostic uses of the compounds and pharmaceutical compositions.

##STR00001##

A catalyst and a method for synthesizing cyclic carbonate using the catalyst are provided. The catalyst includes a metal complex shown in formula (I): ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.4, and R.sup.5 are independently a C1-C25 alkyl group, a C1-C25 alkoxy group, a C3-C8 cycloalkyl group, a C6-C25 aryl group, a C6-C25 aryloxy group, a C7-C25 aralkyl group, a C7-C25 aralkoxy group, or halogen; R.sup.3 is hydrogen, a C1-C25 alkyl group, a C3-C8 cycloalkyl group, a C6-C25 aryl group, a C6-C25 aryloxy group, a C7-C25 aralkyl group, or a C7-C25 aralkoxy group; M is Sn or Ti; X is Cl, Br, I, or OAc; and L represents ether or furan.

A catalyst and a method for synthesizing cyclic carbonate using the catalyst are provided. The catalyst includes a metal complex shown in formula (I): ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.4, and R.sup.5 are independently a C1-C25 alkyl group, a C1-C25 alkoxy group, a C3-C8 cycloalkyl group, a C6-C25 aryl group, a C6-C25 aryloxy group, a C7-C25 aralkyl group, a C7-C25 aralkoxy group, or halogen; R.sup.3 is hydrogen, a C1-C25 alkyl group, a C3-C8 cycloalkyl group, a C6-C25 aryl group, a C6-C25 aryloxy group, a C7-C25 aralkyl group, or a C7-C25 aralkoxy group; M is Sn or Ti; X is Cl, Br, I, or OAc; and L represents ether or furan.

The disclosure relates to special orthoformic acid esters of formula (I), as defined herein, which can be used as thermally labile and acid-labile fragrance storage substances. The disclosure further relates to detergents and cleaning agents, cosmetic agents and air freshening products containing such orthoformic acid esters, as well as to a method for lastingly fragrancing surfaces.